Apex Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Apex Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$22.6M	Buy	1,483,104 +58,678	+4%	+$766K	0.5%	69
2015 Q4	$19.1M	Sell	1,424,426 -12,908	-0.9%	-$200K	0.43%	74
2015 Q3	$20.2M	Buy	1,437,334 +62,058	+5%	+$1.15M	0.46%	71
2015 Q2	$23.4M	Buy	+1,375,276	New	+$19.6M	0.5%	72

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Apex Capital Management's SUPN Position: Q1 2016 in Review

Apex Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 4.1% in Q1 2016, buying an estimated $766K and bringing the position to 1,483,104 shares worth $22.6M. The position accounts for 0.5% of the portfolio, ranked #69.

Apex Capital Management first reported a position in SUPN in Q2 2015 and has held it in 4 quarters since. The position peaked at $23.4M in Q2 2015. 214 funds tracked by Wall St. Rank hold SUPN as of Q1 2016.

Apex Capital Management held 1,483,104 shares of Supernus Pharmaceuticals worth $22.6M as of Q1 2016.
Apex Capital Management bought 58,678 Supernus Pharmaceuticals shares in Q1 2016, an estimated $766K.
Supernus Pharmaceuticals made up 0.5% of Apex Capital Management's portfolio in Q1 2016, its #69 holding.
Apex Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 4 quarters since.
Apex Capital Management's Supernus Pharmaceuticals position peaked at $23.4M in Q2 2015.
214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.